Avicanna Reports Q2 2024 - Seite 2

• Completion of Topical Gel Observational Real-World Evidence Study in patients with musculoskeletal pain and inflammation (“RWE Study”). The RWE Study evaluated patient-reported efficacy of the RHO Phyto CBG Transdermal Gel containing 2% CBD and 1% CBG on a range of clinical conditions including arthritis, osteoarthritis, rheumatoid arthritis, fibromyalgia, muscle and joint pain, localized pain, and post-surgical pain. The RWE Study reported a meaningful improvement in overall Musculoskeletal Health Questionnaire scores (p<0.001) as compared from baseline to one month, specifically, there was a 35.4% improvement reported in health-related domains including symptoms, physical functioning, daily activities and work.
  

• United States Patent and Trademark Office (“USPTO”) issuance of Patent No. US 11,998,632 B2 covering the Corporation’s SEDDS Technology (“Patent”). “SEDDS” or the self-emulsifying drug delivery system is the Company’s drug delivery system technology for oral cannabinoid composition and methods of treating neuropathic pain. Due to the highly lipophilic nature and poor water-solubility of cannabinoids, the formulations currently available in the Canadian market have been generally described as having poor absorption and high variability of onset, and SEDDS offers a route for non-invasive and non-inhalation administration of cannabinoids. 
  

• Symposium on Cannabinoid-based Medicine during May 2024 (“Symposium”). The Symposium brought key opinion leaders and health care providers to explore cannabinoid-based R&D, medicine, and clinical adoption that was hosted at the MaRS Discovery District, Toronto. The Symposium was limited to key opinion leaders, health care practitioners and researchers, covered a range of topics including emerging evidence and practical clinical applications of cannabinoid-based medicine and featured key opinion leaders, clinicians, researchers, and scientists from various academic, research and clinical organizations and hospitals and scientific members of industry. 
  

• The Company completed the Q2 2024 with 32 commercial SKUs and 145 commercial listings representing a 23% growth in listings from Q2 2023. The Company also sold approximately 99,000 units representing a 15% growth in total finished goods sold compared to Q2 2023.  Commercial results of the MyMedi.ca medical cannabis care platform combined with optimization of sales on other channels contributed to margin improvements that yielded consolidated margins of 49% in Canada.